Loading companies…
CP
Circle Pharma, Inc.
United States · Biotech
Circle Pharma discovers macrocycle medicines for cancer and other serious diseases using its MXMO platform, which combines computational, structure-based design with synthetic chemistry to create cell-permeable compounds against difficult protein targets. Its lead programs are investigational and at discovery or preclinical stages.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series E | $92.5M | The Column Group — LeadEli Lilly and Company — ParticipantEuclidean Capital — ParticipantNextech Invest — ParticipantRA Capital Management — Participant |
Investors
The Column GroupLed Series EEli Lilly and CompanyJoined Series EEuclidean CapitalJoined Series ENextech InvestJoined Series ERA Capital ManagementJoined Series ECoverage
Sep 16, 2026Circle Pharma, Inc. · Series ESimilar companies
AnaCardioAnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure.€62.5M · Series B
AventixAventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results.€1.2M · Pre-seed
ATAptadir TherapeuticsRNA therapeutics designed to restore expression of silenced genes€40M · Seed